Compare HSBC Holdings plc (HSBC) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HSBC Holdings plc vs Medpace Holdings Inc — how do they compare? HSBC Holdings plc trades at $92.91 (market cap $311.92B), while Medpace Holdings Inc trades at $617.62 (market cap $16.82B). The key difference: HSBC Holdings plc is far larger — about 18.5× Medpace Holdings Inc's market cap, and HSBC Holdings plc pays a 4.05% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold HSBC Holdings plc for 36 Days and Medpace Holdings Inc for 14 Days on average.
| HSBC | MEDP | |
|---|---|---|
Market Cap | $311.92B | $16.82B |
Volume | 3,546,658 | 223,093 |
Sector | Financials | Health |
52-Week High | $107.86 | $630.19 |
52-Week Low | $65.67 | $393.42 |
Typical Hold Time | 36 Days | 14 Days |
Enterprise Value | $222.19B | $16.44B |
Dividend Yield | 4.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HSBC trades at $92.96, down 0.8% with bearish technical indicators. The bank shows strong profitability with 34.54% net margin and 12.44% ROE, while trading at reasonable valuations (P/E 13.23). Recent earnings show mixed results with Q2 beat but Q1 miss. Analyst sentiment is mixed with 38.1% buy ratings amid strategic expansions in US wealth management and Asian markets.
HSBC presents a balanced opportunity with solid fundamentals offset by near-term technical weakness. Growth initiatives in wealth management and Asian markets provide upside potential, while CFO transition and European restructuring pose execution risks. The stock's valuation remains attractive relative to earnings power.
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
